Arterial hypertension in patients with type 2 diabetes mellitus
DOI:
https://doi.org/10.31053/1853.0605.v70.n2.20243Keywords:
arterial hypertension, mellitus diabetes, cardiovascular risk, non-pharmacological and pharmacological therapyAbstract
Hypertension, diabetes and that cluster of metabolic alterations often referred to as the metabolic syndrome are highly prevalent in Argentina and Latin America and occur frequently as associated conditions (65%). The development of diagnostic and therapeutic recommendations prepared through the joint work
of experts in different areas of medicine is desirable, considering the low rates of control achieved in the real world, and the benefits that can be expected when reasonable objectives are met. Health care resources and priorities, the socio-economic status of the population, and the prevalence of hypertension, diabetes mellitus, and other related diseases vary considerably in different regions of the world and also in different countries within each region, and even in different areas of individual countries. Recommendations to be usefully translated into practice should consider the particular medical and social features of the region where they should be applied and be cost-effective in terms of local needs and possibilities Effectively treatment of hypertension in general and particularly in diabetic patients is one of the major objectives to prevent target organ damage. Unfortunately, in our countries only 25% of the patients are in target.
In this document a rationale therapeutic approach is analyzed for hypertension in diabetic patients. Life style changes and pharmacologic treatment combinations is extensively reporte.
Downloads
References
1. Latin American consensus on hypertension in patients with diabetes type 2 and metabolic syndrome. López-Jaramillo P, Sánchez RA, Diaz M, Cobos L, Bryce A, Parra Carrillo JZ, Lizcano F, Lanas F, Sinay I, Sierra ID, Peñaherrera E, Bendersky M, Schmid H, Botero R, Urina M, Lara J, Foss MC, Márquez G, Harrap S, Ramírez AJ, Zanchetti A; on behalf of the Latin America Expert Group. J Hypertens. 2013 Feb;31(2):223-238.
2. World Health Organization, International Society of Hypertension Writing Group. World Health Organization-International Society of Hypertension statement on management of hypertension. J Hypertens 2003;21:1983-1992.
3. Prevention of Cardiovascular Disease. Guidelines for assessment and management of Cardiovascular Risk. World Health Organization, 2007.
4. Lewington S, Clarke F, Dizilbach N, Peto R, Collins R. Prospective Studies Collection. Age specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-1.
5. Mancia G, de Backer G, Dominiczak A, et al: 2007 Guidelines for the Management of Arterial Hypertension The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007, 25: 1105–1187.
6. Mancia G, Laurent S, Agabiti-Rosei A et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009, 27: 2121 – 2158
7. OPS, Salud de las Américas 2007-2008-2009.
8. OMS: Prevención de las enfermedades crónicas, una inversión vital. 2004.
9. OPS: Las Américas: una población creciente urbana que está envejeciendo. 2004.
10. Sánchez RA, Ayala M, Baglivo H, Velázquez C, Burlando G, Kolmann O, Giménez J,Bendersky M et al, on be- half of the Latin American expert Group. Latin American guidelines on Hypertension. J Hypertens. 2009. 27: 905-922.
11. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr et al. The Seventh Report of the Joint National Committee on prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 report. JAMA 2003; 289:2560-2572.
12. Stamler J, Stamler R, Neaton JD: Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. Arch Intern Med. 1993; 153: 598-615.; Hypertension: Pathophysiology, diagnosis, and management, vols 1 and 2 Ed: Laragh JH and Brenner DM. Published by: Raven Press, New York, 1995 pp: 127-144.).
13. Cuspidi C, Macca G, Sampieri L, Michev I, Salerno M, Fusi V, Severgnini B, Meani S, Magrini F, Zanchetti A. High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. J Hypertens 2001; 19: 2063–2070.
14. Verdecchia P, Porcellati C, Schillaci G, et al. Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension 1994; 24(6): 793-801.
15. Pickering T, James GD, Boddie C, et. al How common is white coat hypertension? JAMA 1988; 259: 225-228.
16. Julius S, Mejia A, Jones K, Krause L, Sork N, Van de Ven C et al. White coat versus sustained borderlin Robles NR, Cancho B: Hipertensión de bata blanca. Nefrología 2002; 22 (Supl. 3): Mancia G, Facchetti R, Bomballi M, Grassi G, Sega R. Long-term risk of mortality associated with selective and combined elevation in office, home and ambulatory blood pressure. Hypertension 2006; 47: 846-853.
17. Ohkubo T, Kiluya M, Metoki H, Asayama K, Obara T, Hashimoto T, Totsuna K, Hoshi H, Saloli H, Imai Y. Prognosis of masked hypertension and white-coat hypertension detected by 24 h. ambulatory blood pressure monitoring. J Am Coll Cardiol 2005; 46: 508-515
18. Fagard RH, Den Broski G, De Cort P. Diagnostic significance of blood pressure measurement in the office, at home and during ambulatory monitoring in older patients in general population. J Hum Hypertens 2005; 19: 801-807.
19. Sorge R, Tromino G, Lanzarotti A, Carugo S, Casana G, Sciavoni R, Valaguesa F, Bombeli M, Giannatasio C, Zanchetti A, Mancia G. Alterations in cardiac structure in patients with isolated office, ambulatory or home hypertension. Data from the general PAMELA population. Circulation 2001; 1104: 1385-92.
20. Parati, G; Stergiou, G S; Asmar, R; Bilo, G; et al. European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. J Hypertens 2008, 26: 1505-1526.
21. Palatini, P. Ambulatory blood pressure monitoring in clinical practice: is being superior good enough?. J Hypertens 2008, 26: 1300-1302.
22. White WB. Ambulatory blood pressure monitoring in clinical practice. N Engl J Med 2003; 348: 2377-2378.
23. O'Brien E, Asmar R, Beilin L, Imai Y, Mallion JM, Mancia G, et al.; European Society of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens. 2003 May; 21[5]: 821-483; 348: 2377-2378.72-76, 2002
24. Lastra G, McFarlane SI, Sowers JR. Treatment of hypertensive patients with anbnormal blood glucose. In Izzo JL, Sica DA and Black HR. Hypertension Primer. Chap. C158, pp. 529-32.2010 25. The HOPE Study Investigators. Effects of an angiotensina-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med 2000;342:145-53.
26. UK Prospective Diabetes Study Group (UKPDS). Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. BMJ 1998;317:703-13.
27. Stassen JA, Fagard R, Thijs L y cols. A randomised double blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997;350:757-64.
28. HOT Study: Hansson L, Zanchetti A, Carruthers SG y cols. Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-62.
29. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:3255-64
30. A.H. Barnett Preventing renal complications in diabetic patients: the Diabetics Exposed to Telmisartan And enalaprIL (DETAIL) study Acta Diabetol (2005) 42:S42–S49.
31. Bakris G, Burgess E, Weir M, Davidai G, Koval S; AMADEO Study Investigators Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int. 2008 Aug;74(3):364-9.
32. The Action to Control Cardiovascular Risk in Diabetes Study Group (ACCORD). Effects of Intensive Glucose Lowering in Type 2 Diabetes. N Engl J Med 2008;358:2545-59.
33. Brenner BM, Cooper ME, De Zeeuw D y cols. The RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type-2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
34. Lewis EJ, Hunsicker LG, Clarke WR y cols. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type-2 diabetes. N Engl J Med 2001;345:851-60.
35. Parving HH, Lehnert H, Bröchner-Mortensen J y cols. The effect of irbesartan on the development of diabetic nephropathy in patients with type-2 diabetes. The IRMA Group. N Engl J Med 2001;345:870-8.
36. NAVIGATOR Study Group, McMurray JJ, Holman RR, Haffner SM y cols. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010;362:1477-1490
37. Dahlöf B, Devereux RB, Kjeldsen SE y cols. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
38. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients with high risk for vascular events. N Engl J Med 2008;358:1547-59.
39. Savage PJ, Pressel, Curb JD y cols. Influence of long term, low dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: The SHEP Cooperative Research Group. Arch Intern Med 1998;158:741-51.
40. ALLHAT officers and coordinators. Major outcomes in high risk Hypertensive Patients randomized to angiotensina convering enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002; 288:2981-87.
41. Dalhöf B, Sever P, Poulter NR, y cols. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo Scandinavian Cardiac Outcomes Trial-Blood pressure lowering arm (ASCOT-BPLA): a multicentre randomised trial. Lancet 2005; 366:815-906.
42. Fujita, T. Mineralocorticoid Receptors, Salt-Sensitive Hypertension, and Metabolic Syndrome. Hypertension 2010;55;813-818
Downloads
Published
Issue
Section
License
Copyright (c) 2013 Universidad Nacional de Córdoba
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The generation of derivative works is allowed as long as it is not done for commercial purposes. The original work may not be used for commercial purposes.
How to Cite
